Impact of lapatinib plus trastuzumab versus single-agent lapatinib on quality of life of patients with trastuzumab-refractory HER2+ metastatic breast cancer.

Saved in:
Bibliographic Details
Title: Impact of lapatinib plus trastuzumab versus single-agent lapatinib on quality of life of patients with trastuzumab-refractory HER2+ metastatic breast cancer.
Authors: Wu, Y.1, Amonkar, M. M.2, Sherrill, B. H.1, O’Shaughnessy, J.3, Ellis, C.2, Baselga, J.4, Blackwell, K. L.5, Burstein, H. J.6
Source: Annals of Oncology. Dec2011, Vol. 22 Issue 12, p2582-2590. 9p.
Database: Academic Search Ultimate
Description
ISSN:09237534
DOI:10.1093/annonc/mdr014